Katja Schulze

ctDNA Analysis in <i>ERBB2</i> -Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial

ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial.

Table S1 from ctDNA Analysis in &lt;i&gt;ERBB2&lt;/i&gt;-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial

Figure S2 from ctDNA Analysis in &lt;i&gt;ERBB2&lt;/i&gt;-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial

Table S2 from ctDNA Analysis in &lt;i&gt;ERBB2&lt;/i&gt;-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial

Figure S1 from ctDNA Analysis in &lt;i&gt;ERBB2&lt;/i&gt;-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial

Table S3 from ctDNA Analysis in &lt;i&gt;ERBB2&lt;/i&gt;-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial

Table S4 from ctDNA Analysis in &lt;i&gt;ERBB2&lt;/i&gt;-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial

Data from ctDNA Analysis in &lt;i&gt;ERBB2&lt;/i&gt;-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial

MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors.

Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non–Small Cell Lung Cancer

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.

Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives

MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2–Altered Advanced Solid Tumors

Artificial Intelligence–Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study

Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study

PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis

AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).

1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC

Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study

Genetic copy number variants, cognition and psychosis: a meta-analysis and a family study

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).

Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies